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Le Kremlin-Bicêtre, Paris, France 
h Centre for Pulmonary Hypertension, Thoraxclinic at Heidelberg University Hospital, Heidelberg, Germany 
i Department of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 
j Medical Clinic I, Department of Pneumology, University Hospital Carl Gustav Carus, Dresden, Germany 
k Center for Pulmonary Vascular Disease, Jewish General Hospital, McGill University, Montreal, Quebec, Canada 
l Department of Pulmonology, St Antonius Ziekenhuis, Nieuwegein, the Netherlands 
m Department of Cardiology, Hospital 12 de Octubre, Madrid, Spain 
n CIBER-CV (CIBER of Cardiovascular Disease), Hospital 12 de Octubre, Madrid, Spain 
o Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada 
p Department of Internal Medicine II, Division of Pneumology, University Medical Center, Regensburg, Germany 
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A B S T R A C T   
Objective: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with 
pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pul-
monary hypertension (CTEPH) following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients 
with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in 
clinical practice. 
Methods: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study 
of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or 
until 30 days after stopping riociguat treatment. Primary safety outcomes were adverse events (AEs) and serious 
adverse events (SAEs) coded using Medical Dictionary for Regulatory Activities preferred terms and System 
Organ Classes version 21.0, collected during routine clinic visits and collated via case report forms. 
Results: In total, 956 patients with CTEPH were included in the analysis. The most common AEs in these patients 
were peripheral edema/edema (11.7%), dizziness (7.5%), right ventricular (RV)/cardiac failure (7.7%), and 
pneumonia (5.0%). The most common SAEs were RV/cardiac failure (7.4%), pneumonia (4.1%), dyspnea 
(3.6%), and syncope (2.5%). Exposure-adjusted rates of hemoptysis/pulmonary hemorrhage and hypotension 
were low and comparable to those in the long-term extension study of riociguat (Chronic Thromboembolic 
Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial [CHEST-2]). 
Conclusion: Data from EXPERT show that in patients with CTEPH, the safety of riociguat in routine practice was 
consistent with the known safety profile of the drug, and no new safety concerns were identified.   
1. Introduction 
Chronic thromboembolic pulmonary hypertension (CTEPH) is a poten-
tially fatal condition characterized by obstruction of the pulmonary vascu-
lature by residual organized thrombi resulting in increased pulmonary 
vascular resistance (PVR), progressive vascular remodeling and pulmonary 
hypertension (PH), and subsequently right ventricular (RV) failure [1–5]. 
The treatment of choice in CTEPH is pulmonary endarterectomy (PEA), 
which potentially normalizes hemodynamics [5–8]. Up to 40% of patients 
are inoperable, however, and up to 51% exhibit persistent or recurrent 
CTEPH after PEA [6–14]. 
Riociguat is a first-in-class soluble guanylate cyclase stimulator recom-
mended in European Respiratory Society/European Society of Cardiology 
guidelines for the treatment of patients with inoperable CTEPH or persis-
tent/recurrent CTEPH after surgery [1]. Its efficacy and tolerability have 
been demonstrated in clinical trials [15,16]. Agents that have been approved 
for pulmonary arterial hypertension (PAH) include prostacyclin analogs, 
endothelin receptor antagonists (ERAs), and phosphodiesterase type 5 in-
hibitors (PDE5i). With the exception of treprostinil in selected patients, these 
are not licensed for use in the treatment of patients with CTEPH, but can be 
administered off-label. Balloon pulmonary angioplasty (BPA) is a potentially 
effective option for selected inoperable patients [1,17]. 
EXPosurE Registry RiociguaT in patients with PH (EXPERT) was a 
prospective, non-interventional registry to monitor the long-term safety 
of riociguat in clinical practice. 
2. Methods 
2.1. Study design 
EXPERT (NCT02092818) was an international, multicenter, prospec-
tive, uncontrolled, non-interventional cohort study in patients treated with 
riociguat in 28 countries. The design is described in detail elsewhere [18]. 
EXPERT was linked with the Comparative, Prospective Registry of Newly 
Initiated Therapies for Pulmonary Hypertension (COMPERA [https://com 
pera.org/]), one of the largest global academic PH registries. This was 
consistent with guidance from regulatory authorities to use existing regis-
tries. EXPERT was conducted in accordance with good pharmacovigilance 
practices and was not requested, but was accepted, by the European Medi-
cines Agency for the collection of additional long-term post-approval data on 
riociguat. 
Patients were followed for 1–4 years from enrollment (including post- 
treatment safety follow-up) during a recruitment period of 3 years or until 
30 days after stopping riociguat treatment. Data—including patient 
demographics, disease characteristics, riociguat dosing, hemodynamic pa-
rameters, changes in treatment, biomarkers, laboratory variables, adverse 
events (AEs) and serious adverse events (SAEs)—were collected at baseline 
and during routine clinical follow-up visits approximately every 
3–6 months. Data were collected using a case report form (CRF) based on the 
COMPERA CRF, extended to obtain riociguat safety data. 
2.2. Patients 
Patients who started treatment or were already being treated with rio-
ciguat were eligible for inclusion. Patients with disease duration ≥ 6 months 
were defined as prevalent, and those diagnosed within < 6 months of 
enrollment were defined as incident. Patients were defined as riociguat- 
pretreated if they had been receiving riociguat for ≥ 3 months before reg-
istry entry and as riociguat-newly treated if they had been receiving riociguat 
for <3 months before entry. Riociguat-newly treated patients were therefore 
not necessarily incident patients and could have received PAH-approved 
therapy before riociguat. Newly treated patients were further categorized 
as switched or non-switched. Switched patients were newly treated patients 
who had stopped prior therapy ≤10 days before commencing riociguat. 
2.3. Safety assessments 
The primary safety outcomes were AEs and SAEs, coded using Medical 
Dictionary for Regulatory Activities (MedDRA) preferred terms and Sys-
tem Organ Classes version 21.0. Secondary safety outcomes included AEs 
and SAEs of special interest (hypotension and hemoptysis/pulmonary 
hemorrhage). This report focuses on AEs and SAEs occurring during the 
treatment phase (onset date ≤ 2 days after the most recent dose of rioci-
guat). An AE was considered serious if it: resulted in death, was life- 
threatening, required inpatient hospitalization or prolongation of hos-
pitalization (with specific exceptions, defined in the protocol), resulted in 
persistent or significant disability or incapacity, was a congenital ab-
normality or birth defect, or was medically important. AEs and SAEs were 
classified as drug-related according to the investigator’s judgment. 
Deaths were analyzed in terms of all SAEs with a fatal outcome with onset 
during the treatment phase and the post-treatment phase (onset date 
> 2 days after discontinuation until the end of 30-day safety follow-up). 
2.4. Statistical methods and populations analyzed 
EXPERT was an observational study. All variables and outcomes, 
including comparisons between predefined groups (such as newly 
treated versus pretreated patients and prevalent versus incident 
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patients) were analyzed descriptively. Statistical analyses of these 
comparisons were not performed because they would be of limited value 
without adjustment for differences between the groups. All analyses 
were performed with SAS 9.3. Categorical variables were analyzed using 
frequency tables and continuous variables by summary statistics (mean 
± standard deviation [SD], median, and minimum–maximum range). 
The evaluable population consisted of all enrolled patients who did not 
withdraw consent and had received at least one dose of riociguat with 
dosing data available. Summary statistics and changes from baseline 
were calculated for 6-min walking distance (6MWD), World Health 
Organization functional class (WHO FC), Borg Dyspnea Index, EuroQoL 
5-dimensional Visual Analog Score (EQ-5D VAS), hemodynamic pa-
rameters, and biomarkers. This paper describes the results in patients 
with CTEPH. Results in patients with PAH are described separately [18]. 
3. Results 
3.1. Patient disposition 
The evaluable population with CTEPH consisted of 956 patients of 
whom 537 (56.2%) were riociguat-pretreated and 419 (43.8%) were 
riociguat-newly treated. Approximately 86% of patients overall 
completed the study (Fig. 1). 
3.2. Demographics and baseline characteristics 
The mean age of the patients was 66.3 ± 13.7 years; 570 patients 
(59.6%) were women. CTEPH was prevalent in 713 patients (74.6%), 
incident in 197 (20.6%), and unknown in 46 (4.8%). At baseline, riociguat 
was administered in combination with other PH-approved therapy in 198 
patients (20.7%): with ERAs in 170 (17.8% [bosentan, 7.0%; macitentan, 
7.0%; and ambrisentan, 3.8%]), prostanoids in 9 (0.9% [iloprost, 0.6%; 
intravenous treprostinil, 0.2%; and intravenous epoprostenol, 0.1%]), 
and both an ERA and prostanoid in 19 (2.0%). No patient received 
concomitant PDE5i. At Visit 6 (month 33− < 39), 27.9% of patients were 
receiving combination therapy. In total, 901 patients (94.2%) had at least 
one comorbidity. Other baseline demographics are shown in Table 1. The 
operability status of the patients is shown in Fig. 2. 
3.3. Riociguat safety 
3.3.1. Total CTEPH population 
In the total population with CTEPH, the median (range) duration of 
observation and riociguat treatment was 504.0 (0.0–1367.0) days and 
493.5 (0.0–1367.0) days, respectively. In total, 615 patients (64.3%) 
experienced AEs and 365 (38.2%) experienced SAEs. These events were 
considered drug-related by the investigator in 148 (15.5%) and 34 (3.6%) 
patients, respectively. The most common AEs and SAEs are shown in 
Table 2. Discontinuation due to AEs and SAEs occurred in 55 patients 
(5.8%) and 38 patients (4.0%), respectively. The most common AEs or 
SAEs leading to discontinuation are shown in Supplementary Table 2. 
Safety data for patients according to use of riociguat as monotherapy or in 
combination with other PAH-approved drugs are shown in Supplemen-
tary Table 3. Rates of AEs and SAEs (68.2–88.9% and 44.1–66.7%, 
respectively) were numerically higher with prostanoid-containing regi-
mens (78.9–88.9% and 57.9–66.7%, respectively) than with riociguat 
monotherapy or riociguat + ERA (62.8–68.2% and 36.0–44.1%, respec-
tively), but the numbers of patients receiving prostanoids were small. 
Hemorrhages were reported in 110 patients (11.5%) and serious 
hemorrhages in 57 patients (6.0%). These events were considered by the 
investigator to be related to riociguat in nine (0.9%) and four patients 
(0.4%), respectively. Three patients (0.3%) discontinued riociguat as a 
result of a hemorrhage. The most frequently occurring hemorrhages 
were epistaxis in 30 patients (3.1%) and hemoptysis in 26 patients 
(2.7%). The most common serious hemorrhages were hemoptysis in 16 
patients (1.7%) and gastrointestinal hemorrhage in five patients (0.5%). 
Of all patients who experienced a hemorrhage, 78 were recorded as 
receiving a vitamin K antagonist (VKA) and 24 as receiving non-VKA 
oral anticoagulants (NOACs). Hemoptysis and pulmonary hemorrhage 
were considered AEs of special interest and are discussed further below. 
3.3.2. Safety in prevalent vs. incident patients 
A post hoc analysis compared prevalent patients (disease duration ≥6 
months) (n =713) with incident patients (diagnosed within <6 months of 
enrollment) (n = 197) according to disease duration data available at 
baseline. Disease characteristics, including 6MWD and WHO FC, indi-
cated a more severe disease status in incident patients compared with 
prevalent patients (data not shown). Median disease duration was 1.8 
(range, 0.0–6.0) months in incident patients and 3.2 (range, 0.5–39.7) 
years in prevalent patients. AEs were reported in 471 prevalent patients 
(66.1%) and 119 incident patients (60.4%), and SAEs in 276 (38.7%) and 
73 (37.1%) prevalent and incident patients, respectively. 
3.3.3. Comparison between riociguat-pretreated and riociguat-newly 
treated patients 
Compared with riociguat-pretreated patients, riociguat-newly 
treated patients had a numerically shorter disease duration, shorter 
6MWD, a higher proportion of WHO FC III/IV disease, and a greater 
proportion of incident disease (Table 3). More than 90% of patients in 
both groups had at least one comorbidity. Approximately 89% of 
riociguat-pretreated patients and 83% of riociguat-newly treated pa-
tients completed the study (Fig. 3). Of the riociguat-newly treated pa-
tients, 72 (17.2%) had switched from previous PAH-approved therapy: 
65 (15.5%) from PDE5i, 5 (1.2%) from a prostanoid, and 12 (2.9%) from 
an ERA (some patients switched from more than one prior therapy). 
AEs were reported in 270 riociguat-newly treated patients (64.4%) and 
345 riociguat-pretreated patients (64.2%). SAEs were reported in 166 
riociguat-newly treated patients (39.6%) and 199 riociguat-pretreated 
Fig. 1. Patient disposition. 
CTEPH, chronic thromboembolic pulmonary hypertension. The numbers and 
percentages refer to the total CTEPH population enrolled (n = 969). Chart 
shows primary reason for not completing per protocol. 
aOther reasons for discontinuation are shown in Supplementary Table 1. 
H.-A. Ghofrani et al.                                                                                                                                                                                                                           
Respiratory Medicine 178 (2021) 106220
4
patients (37.1%). Numerically more AEs and SAEs in riociguat-newly 
treated patients were considered drug-related and led to drug discontinua-
tion than in riociguat-pretreated patients (Table 4). The types of AEs and 
SAEs were generally similar between the two groups. The most common AEs 
or SAEs leading to discontinuation are shown in Supplementary Table 4. 
Safety results in switched patients were generally similar to those in non- 
switched patients (data not shown). In riociguat-pretreated and riociguat- 
newly treated patients, AEs and SAEs were more frequent with combina-
tion therapy than with monotherapy (Supplementary Table 5). 
3.4. AEs and SAEs of special interest 
In general, AEs and SAEs of special interest were infrequent 
(Table 5). All of the 16 patients with serious hemoptysis/pulmonary 
hemorrhage overall were recorded as receiving concomitant anticoag-
ulants, three as receiving concomitant antiplatelet therapy, and one as 
receiving a concomitant prostanoid. The incidence of hypotension was 
low across all subgroups (Supplementary Table 6). 
3.5. AEs associated with PEA or BPA 
In total, 47 patients (4.9%) underwent PEA (one operation in 44 patients 
[4.6%] and two operations in three patients [0.3%]). Within 10 days after 
PEA, nine of these patients (19.1%) had an AE, six (12.8%) had an SAE, and 
one (2.1%) had an AE-related death. No episode of hemoptysis was reported 
within 10 days following PEA. Also, 89 patients (9.3%) underwent BPA 
(mean: 2.1 ± 1.4 sessions; median: 2; range: 1–8) during the study. Within 
10 days after BPA, six of these patients (6.7%) had an AE and six (6.7%) had 
Table 1 
Baseline demographics and disease characteristics in the total CTEPH population (n = 956).  
Characteristic Mean ± SD or n (%) Characteristic Mean ± SD or n (%) 
Age, years 66.3 ± 13.7 Riociguat daily dose at initial study visit, mg  
Age group, years Mean 6.9 ± 1.4 (n = 934) 
< 65 366 (38.3) Median (range) 7.5 (1.5− 7.5) (n = 934) 
65 to < 75 260 (27.2)   
≥ 75 330 (34.5)   
BMI, kg/m2 28.6 ± 15.2 Riociguat median daily dose at initial study visit, mg  
BMI category, kg/m2  ≤ 2.5 13 (1.4) 
< 18.5 24 (2.5) > 2.5 to 4.5 108 (11.3) 
18.5 to < 25 290 (30.3) > 4.5 to 6 90 (9.4) 
25 to < 30 348 (36.4) > 6 to 7.5 723 (75.6) 
≥ 30 294 (30.8) Missing 22 (2.3) 
Smoking status Concomitant CCB 22 (2.3) 
Never 602 (63.0)   
Former 314 (32.8) Concomitant anticoagulation therapy  
Current 40 (4.2) Oral anticoagulation 861 (90.1) 
Age at initial PH diagnosis, years 62.7 ± 14.5 Vitamin K antagonist 506 (52.9) 
Median (IQR) disease duration, years 2.1 (0.7− 4.9) Direct oral anticoagulant 190 (19.9)   
Other oral anticoagulationb 159 (16.6)   
Other anticoagulantb 66 (6.9)       
Concomitant antiplatelet agents 44 (4.6) 
WHO FC, % (I/II/III/IV/unknown) 4.0/38.2/50.1/3.0/4.7 Comorbidity 
BNP, pg/mL (median, range) 131 (5− 5844) (n = 148) At least one medical history finding 901 (94.2) 
NT-proBNP, pg/mL (median, range) 602 (16− 177 759) (n = 540) Arterial hypertension 445 (46.5) 
6MWD, m 365 ± 128 Venous thromboembolism 431 (45.1) 
6MWD Thyroid disease 183 (19.1) 
< 320 ma 290 (30.3) Diabetes mellitus 123 (12.9) 
≥ 320 m 521 (54.5) Cancer 123 (12.9) 
< 380 m 421 (44.0) Coronary heart disease 122 (12.8) 
≥ 380 ma 390 (40.8) Obstructive sleep apnea 99 (10.4) 
Missing 145 (15.2) History of hemoptysis/lung bleeding 37 (3.9) 
EQ-5D VAS 62.3 ± 20.6 (n = 229) Other 759 (79.4) 
Borg Dyspnea Index 3.8 ± 2.2 (n = 701)   
mPAP, mmHg 43.0 ± 11.5 (n = 850)   
PVR, dyn⋅s⋅cm− 5 652 ± 502 (n = 767)   
PAWP, mmHg 11.1 ± 5.0 (n = 809)   
Cardiac index, L/min/m2 2.8 ± 4.4 (n = 756)   
RAP, mmHg 9.0 ± 5.6 (n = 710)   
SvO2, % 63.7 ± 9.2 (n = 613)   
6MWD, 6-minute walking distance; BMI, body mass index; BNP, brain natriuretic peptide; CCB, calcium channel blocker; CTEPH, chronic thromboembolic pulmonary 
hypertension; EQ-5D VAS, EuroQoL 5-dimensional Visual Analog Score; IQR, interquartile range; mPAP, mean pulmonary artery pressure; NT-proBNP, N-terminal 
prohormone of brain natriuretic peptide; PAWP, pulmonary artery wedge pressure; PEA, pulmonary endarterectomy; PH, pulmonary hypertension; PVR, pulmonary 
vascular resistance; RAP, right atrial pressure; SD, standard deviation; SvO2, saturated venous oxygen; WHO FC, World Health Organization functional class. 
Data are mean ± SD or number (%) unless otherwise stated. 
Results are for all patients (n = 956) unless otherwise stated. 
a Thresholds chosen (380 m prespecified) based on available (6MWD) cohort data at the time indicating good or poor prognosis in PAH. 
b As indicated by the investigator on the CRF. 
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an SAE. No AE-related deaths were reported. The AEs included hemoptysis 
in two patients. Both events resolved, and neither was considered related to 
riociguat. None of the AEs reported within 10 days after PEA or BPA was 
considered related to riociguat. 
3.6. Efficacy assessments 
Results for indicators of efficacy (6MWD, Borg Dyspnea Index, 
EQ-5D VAS, hemodynamic measurements, and biomarkers) have not 
been the focus of this non-interventional study; many data were missing, 
and values varied greatly between patients. Selection bias for repeat 
efficacy assessments could confound the results. These results are 
therefore not shown or discussed here. 
3.7. Deaths and fatal SAEs 
Of the 956 patients with CTEPH, 101 (10.6%) (44 riociguat-newly 
treated patients [10.5%] and 57 riociguat-pretreated patients [10.6%]) 
died or experienced an SAE with a fatal outcome with onset during the study. 
These SAEs began during the treatment phase in 93 patients (9.7%); 38 
riociguat-newly treated patients (9.1%) and 55 riociguat-pretreated patients 
(10.2%). Fatal SAEs with post-treatment onset occurred in six riociguat- 
newly treated patients (1.4%) and two riociguat-pretreated patients 
(0.4%). The most common fatal SAEs in the total CTEPH population were RV 
failure/cardiac failure in 27 patients (2.8%), followed by cardiac arrest, 
pneumonia, sepsis, and hemoptysis, each in three patients (0.3%). In 19 
patients (2.0%), the SAE was listed as death (cause unknown). Two deaths 
were considered related to riociguat by the investigator. In one case the cause 
of death was hemoptysis, which occurred more than 2 years after therapy 
was initiated in a patient receiving concurrent anticoagulant medication. 
The other case was death from RV failure/cardiac failure, which occurred 
10 days after the last dose of riociguat and was attributed to lack of efficacy of 
riociguat rather than an AE of the drug. 
Estimated survival rates in the total CTEPH population at 1, 2, and 3 years 
were 94.7% (95% CI, 92.9–96.0%), 85.7% (95% CI, 82.4–88.4%), and 
79.3% (95% CI, 74.0–83.6%), respectively. Kaplan− Meier survival curves 
for riociguat-newly treated and riociguat-pretreated patients are shown in 
Fig. 4. 
In the post hoc analysis assessing patients according to disease dura-
tion, death during the treatment period occurred in 77 prevalent patients 
(10.8%) and 14 incident patients (7.1%). Four prevalent patients (0.6%) 
and four incident patients (2.0%) died during the 30-day safety follow-up. 
4. Discussion 
4.1. Safety findings 
EXPERT provided data on the safety and tolerability of riociguat in 
more than 950 patients with CTEPH in real-world clinical practice. The 
types of AEs observed were consistent with those reported in Chronic 
Thromboembolic Pulmonary Hypertension Soluble Guanylate Cycla-
se–Stimulator Trial-1 (CHEST-1) [15], CHEST-2 [16,19], and the CTEPH 
Early Access Study [20], with no new safety signals identified. The most 
common events (e.g., peripheral edema/edema, dizziness, and dyspnea) 
were consistent with symptoms of the underlying disease or with 
vasodilatation by riociguat. Although the numbers of patients under-
going BPA or PEA were small, there was no evidence of an increased risk 
of drug-related events shortly after these procedures. The 
exposure-adjusted rate of hypotension (2.7 events per 100 patient-years) 
was lower than that reported in CHEST-2 (4.0 events per 100 
patient-years) [19]. The rates of hemoptysis/pulmonary hemorrhage 
were similar (2.2 and 2.8 events per 100 patient-years in EXPERT and 
CHEST-2 [19], respectively). Most patients were receiving anticoagu-
lants as required by CTEPH treatment guidelines: these may have 
contributed to the bleeding AEs. A separate publication comparing 
hemorrhagic and thrombotic/embolic events in patients receiving VKAs 
or NOACs at baseline is in preparation. In patients receiving riociguat as 
part of a combination regimen, the incidences of AEs and SAEs were 
higher than in patients receiving monotherapy. These data should be 
interpreted with caution as they are descriptive, they are not adjusted 
for differences between the combination and monotherapy groups, they 
refer to treatment at baseline, and the numbers of patients receiving 
prostanoids were small. Clinical experience with riociguat shows an 
increased frequency of some AEs such as hypotension, dizziness, and 
edema during dose adjustment [21,22]. These effects, described in the 
reference safety information for the drug, have been attributed to the 
vasodilatory properties of riociguat [21]. Although the overall fre-
quency of AEs or SAEs did not differ greatly between riociguat-newly 
treated and riociguat-pretreated patients, numerically more events of 
hypotension were reported in newly treated patients, as was discontin-
uation because of AEs or SAEs. The higher frequency of hypotension 
might be partly explained by a more severe disease state (as indicated by 
6MWD and WHO FC) and partly by more frequent monitoring during 
dose-adjustment periods. For riociguat-pretreated patients, bias may be 
introduced, because those who had to discontinue the drug because of 
AEs, or who died, could not be documented in the study. Patients 
enrolled in disease registries as prevalent cases may be more likely to 
have stable disease than incident patients [23]. In our post hoc analysis, 
Fig. 2. Operability status. 
BPA, balloon pulmonary angioplasty; CTEPH, chronic thromboembolic pul-
monary hypertension; PEA, pulmonary endarterectomy. Persistent CTEPH after 
PEA or BPA were determined by the investigator. 
Table 2 
Most common AEs and SAEs in the total CTEPH population (n = 956).  
AEsa n (%) 
Peripheral edema/edema 112 (11.7)b 
Dyspnea 81 (8.5) 
RV failure/cardiac failure 74 (7.7)c 
Dizziness 72 (7.5) 
Pneumonia 48 (5.0) 
SAEsd 
RV failure/cardiac failure 71 (7.4)e 
Pneumonia 39 (4.1) 
Dyspnea 34 (3.6) 
Syncope 24 (2.5) 
PHf 22 (2.3) 
AE, adverse event; CTEPH, chronic thromboembolic pulmonary hy-
pertension; PH, pulmonary hypertension; RV, right ventricular; SAE, 
serious adverse event. 
Note. Patients with peripheral edema/edema, or RV failure/cardiac 
failure could have both events. 
a Preferred-term AEs reported in ≥ 5% of patients. 
b Including peripheral edema in 73 patients (7.6%) and edema in 
42 patients (4.4%). 
c Including RV failure in 61 patients (6.4%) and cardiac failure in 
16 patients (1.7%). 
d Preferred-term SAEs reported in ≥ 2% of patients. 
e Including RV failure in 59 patients (6.2%) and cardiac failure in 
15 patients (1.6%). 
f Preferred term for worsening of the condition. 
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Table 3 
Baseline demographics and disease characteristics of riociguat-pretreated and riociguat-newly treated patients.   
Riociguat-pretreateda (n = 537) Riociguat-newly treatedb (n = 419) 
Age, years 65.9 ± 14.1 66.8 ± 13.3  
Age group, years, n (%)   
< 65 218 (40.6) 148 (35.3) 
65 to < 75 138 (25.7) 122 (29.1) 
≥ 75 181 (33.7) 149 (35.6)  
Female sex, n (%) 337 (62.8) 233 (55.6)  
BMI, kg/m2 29.1 ± 19.5 28.0 ± 6.3  
BMI category, kg/m2, n (%)   
< 18.5 15 (2.8) 9 (2.1) 
18.5 to < 25 164 (30.5) 126 (30.1) 
25 to < 30 191 (35.6) 157 (37.5) 
≥ 30 167 (31.1) 127 (30.3)  
Smoking status, n (%)   
Never 332 (61.8) 270 (64.4) 
Former 181 (33.7) 133 (31.7) 
Current 24 (4.5) 16 (3.8)  
Prevalent (disease duration ≥ 6 months), n (%) 481 (89.6) 232 (55.4) 
Incident (disease duration < 6 months) 28 (5.2) 169 (40.3) 
Duration status unknown, n (%) 28 (5.2) 18 (4.3)  
Age at initial PH diagnosis, years 61.6 ± 14.8 (n = 509) 64.2 ± 13.9 (n = 403)  
Median (IQR) PH disease duration, years 2.9 (1.5–5.6) 0.8 (0.2–4.0)  
Persistent CTEPH following PEA, n (%) 133 (24.8) 74 (17.7)  
Persistent CTEPH following BPA, n (%) 16 (3.0) 10 (2.4)  
WHO FC, % (I/II/III/IV/unknown) 5.6/45.1/43.6/2.8/3.0 1.9/29.4/58.5/3.3/6.9  
BNP, pg/mL (median, range) 107 (5–3560) (n = 79) 171 (6–5844) (n = 69)  
NT-proBNP, pg/mL (median, range) 483 (16–177 759) (n = 320) 813 (17–48 858) (n = 220)  
6MWD, m 382 ± 122 (n = 477) 341 ± 133 (n = 334)  
6MWD, n (%)   
< 320 mc 152 (28.3) 138 (32.9) 
≥ 320 m 325 (60.5) 196 (46.8) 
< 380 m 219 (40.8) 202 (48.2) 
≥ 380 mc 258 (48.0) 132 (31.5) 
Missing 60 (11.2) 85 (20.3)  
EQ-5D VAS 63.6 ± 19.7 (n = 144) 60.1 ± 22.1 (n = 85)  
Borg Dyspnea Index 3.7 ± 2.2 (n = 403) 4.0 ± 2.3 (n = 298)  
mPAP, mmHg 43.3 ± 11.8 (n = 462) 42.8 ± 11.2 (n = 388)  
PVR, dyn•s•cm-5 675 ± 575 (n = 413) 626 ± 400 (n = 354)  
PAWP, mmHg 11.2 ± 5.0 (n = 436) 10.9 ± 4.9 (n = 373)  
Cardiac index, L/min/m2 2.8 ± 5.0 (n = 409) 2.7 ± 3.7 (n = 347)  
RAP, mmHg 9.3 ± 5.9 (n = 389) 8.6 ± 5.1 (n = 321)  
SvO2, % 63.6 ± 9.5 (n = 323) 63.9 ± 8.9 (n = 290)  
Riociguat daily dose at initial study visit, mg   
Mean 7.1 ± 1.1 6.6 ± 1.6 (n = 397) 
Median (range) 7.5 (1.5–7.5) 7.5 (1.5–7.5) (n = 397)  
(continued on next page) 
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rates of AEs and SAEs were similar between prevalent and incident pa-
tients, indicating that the higher proportion of incident patients in the 
riociguat-newly treated group did not disadvantage them in terms of 
safety. There is no explanation for the greater number of deaths in 
prevalent patients than incident patients but it may be related to the 
longer CTEPH disease duration in the prevalent group. 
4.2. Comparison with other studies 
Compared with the 247 non-operable patients described in the in-
ternational prospective CTEPH registry [9,24], CTEPH patients in 
EXPERT had less severe functional impairment, with 53.1% categorized 
as WHO FC III/IV at baseline versus 83.0% and a slightly higher mean 
6MWD at baseline (365 vs. 315 m). The international registry enrolled 
only incident patients, whereas 74.6% of patients with CTEPH in EXPERT 
had prevalent disease. In a prospective study of 392 patients newly 
diagnosed with CTEPH in Germany, riociguat was the initial treatment in 
81.1% of patients who received medical therapy, illustrating the impor-
tance of obtaining safety data for riociguat [25]. The patients in this study 
had generally similar characteristics to those in the EXPERT population. 
The estimated survival rate in patients with CTEPH in EXPERT (94.7%, 
85.7%, and 79.3% at 1, 2, and 3 years, respectively) appears to be higher 
than in non-operable patients in the international CTEPH registry (88%, 
79%, and 70% at 1, 2, and 3 years, respectively) [24], non-PEA patients in 
the Giessen registry (84.5% at 1 year and 72.5% at 
3 years) [26], US veterans evaluated in a retrospective analysis (89.2%, 
81.4%, and 72.7% at 1, 3, and 5 years, respectively) [27], and patients in 
several other registries [13,14,28–30]. In an analysis from COMPERA, 561 
medically treated patients with CTEPH were graded as at low, intermediate, 
or high risk for death based on their WHO FC, 6MWD, BNP/NT-proBNP, 
Table 3 (continued )  
Riociguat-pretreateda (n = 537) Riociguat-newly treatedb (n = 419) 
Riociguat median daily dose at initial study visit, mg, n (%)   
≤2.5 6 (1.1) 7 (1.7) 
> 2.5 to 4.5 34 (6.3) 74 (17.7) 
> 4.5 to 6 51 (9.5) 39 (9.3) 
> 6 to 7.5 446 (83.1) 277 (66.1) 
Missing 0 22 (5.3)  
PAH-approved regimen at initial study visit, n (%)   
Riociguat monotherapyd 403 (75.1) 355 (84.7) 
Riociguat combination therapye,f 134 (25.0) 64 (15.3) 
Riociguat + ERA 112 (20.9) 58 (13.8) 
Riociguat + ambrisentan 21 (3.9) 15 (3.6) 
Riociguat + bosentan 47 (8.8) 20 (4.8) 
Riociguat + macitentan 44 (8.2) 23 (5.5) 
Riociguat + prostanoid 6 (1.1) 3 (0.7) 
Riociguat + iloprost 3 (0.6) 3 (0.7) 
Riociguat + intravenous treprostinil 2 (0.4) 0 (0.0) 
Riociguat + intravenous epoprostenol 1 (0.2) 0 (0.0) 
Riociguat + ERA + prostanoid 16 (3.0) 3 (0.7)  
Concomitant CCB, n (%) 13 (2.4) 9 (2.1)  
Concomitant anticoagulation, n (%)   
Oral anticoagulation 482 (89.8) 379 (90.5) 
Vitamin K antagonist 311 (57.9) 195 (46.5) 
Direct oral anticoagulant 84 (15.6) 106 (25.3) 
Other oral anticoagulationg 87 (16.2) 72 (17.2) 
Other anticoagulantg 34 (6.3) 32 (7.6)  
Concomitant antiplatelet agents, n (%) 16 (3.0) 28 (6.7)  
Comorbidity, n (%)   
At least one medical history finding 509 (94.8) 392 (93.6) 
Arterial hypertension 231 (43.0) 214 (51.1) 
Venous thromboembolism 223 (41.5) 208 (49.6) 
Thyroid disease 100 (18.6) 83 (19.8) 
Cancer 67 (12.5) 56 (13.4) 
Coronary heart disease 67 (12.5) 55 (13.1) 
Diabetes mellitus 66 (12.3) 57 (13.6) 
Obstructive sleep apnea 65 (12.1) 34 (8.1) 
History of hemoptysis/lung bleeding 23 (4.3) 14 (3.3) 
Other 428 (79.7) 331 (79.0) 
6MWD, 6-min walking distance; BMI, body mass index; BNP, brain natriuretic peptide; BPA, balloon pulmonary angioplasty; CCB, calcium channel blocker; CTEPH, 
chronic thromboembolic pulmonary hypertension; EQ-5D VAS, EuroQoL 5-dimensional Visual Analog Score; ERA, endothelin receptor antagonist; IQR, interquartile 
range; mPAP, mean pulmonary artery pressure; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; PAH, pulmonary arterial hypertension; PAWP, 
pulmonary artery wedge pressure; PEA, pulmonary endarterectomy; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; RAP, right atrial pressure; SD, 
standard deviation; SvO2, saturated venous oxygen; WHO FC, World Health Organization functional class. 
Data are mean ± SD or number (%), unless otherwise stated. 
a Receiving riociguat for ≥ 3 months before entry (n = 537 unless otherwise indicated). 
b Receiving riociguat for < 3 months before entry (n = 419 unless otherwise indicated). 
c Thresholds chosen (380 m prespecified) based on available (6MWD) cohort data at the time indicating good or poor prognosis in PAH. 
d Patients receiving riociguat but no ERA or prostanoid. 
e Patients receiving riociguat + ERA or prostanoid or both. 
f No patient received concomitant PDE5i during the study. 
g As indicated by the investigator on the CRF. 
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RAP, CI, and SvO2 [31]. The estimated 1-year survival rate was 98.6%, 
94.9%, and 75.5% in the low-, intermediate-, and high-risk groups, respec-
tively. The baseline characteristics of CTEPH patients in EXPERT and their 
estimated survival were closest to those of the intermediate-risk COMPERA 
group. 
Registries provide important information about the safety of drugs in 
clinical practice and thus supplement the information gained from 
selected populations under the closely controlled conditions of clinical 
trials. They may also detect previously unsuspected safety signals. No 
such signals were identified in EXPERT. Limitations inherent in regis-
tries including confounding, lack of randomization, missing values, and 
the hazards of generalizing data from the registry population to other 
populations [32], also apply to EXPERT. In addition, EXPERT was 
designed to collect safety information on riociguat; it was not designed 
to provide data on the long-term efficacy of this drug. Strengths of 
EXPERT include the relatively long observation time (median: 
504 days), the large number (956) of patients with CTEPH, the large 
proportion of patients completing the study. The planned enrollment for 
the entire study was 900 patients to allow for detection of ≥ 3 “un-
common” AEs with an incidence ≥ 0.5%. Given that 956 patients with 
CTEPH were enrolled, there were enough patients in the CTEPH cohort 
alone to achieve this power level. The availability of safety data in 
Fig. 3. Disposition of riociguat-pretreated and riociguat-newly treated patients with CTEPH. Chart shows primary reason for discontinuation. 
aOther reasons for not completing the study are listed in Supplementary Table 1. 
Table 4 
Safety summary in riociguat-pretreated and riociguat-newly treated patients with CTEPH.   
Riociguat-pretreateda (n = 537) Riociguat-newly treatedb (n = 419) 
AEs, n (%)   
Any AE 345 (64.2) 270 (64.4) 
Most common AEsc, n (%)   
Peripheral edema/edema 73 (13.6)d 39 (9.3)e 
Dyspnea 50 (9.3) 31 (7.4) 
Dizziness 42 (7.8) 30 (7.2) 
RV failure/cardiac failure 40 (7.4)f 34 (8.1)g 
Pneumonia 31 (5.8) 17 (4.1) 
Cough 27 (5.0) 16 (3.8) 
Hypotension 13 (2.4) 24 (5.7) 
Dyspepsia 12 (2.2) 21 (5.0) 
Any drug-related AEh 53 (9.9) 95 (22.7) 
Discontinuation due to AE 21 (3.9) 34 (8.1) 
SAEs, n (%)   
Any SAE 199 (37.1) 166 (39.6) 
Most common SAEsi, n (%)   
RV failure/cardiac failure 39 (7.3)j 32 (7.6)k 
Pneumonia 26 (4.8) 13 (3.1) 
Dyspnea 17 (3.2) 17 (4.1) 
Syncope 14 (2.6) 10 (2.4) 
PHl 15 (2.8) 7 (1.7) 
Pulmonary embolism 3 (0.6) 9 (2.1) 
Any drug-related SAEh 13 (2.4) 21 (5.0) 
Discontinuation due to SAE 17 (3.2) 21 (5.0) 
AE, adverse event; PH, pulmonary hypertension; RV, right ventricular; SAE, serious adverse event. 
a Receiving riociguat for ≥ 3 months before entry. Median (range) duration of observation and riociguat treatment (days): 532.0 (0.0–1346.0); 506.0 (0.0–1346.0). 
b Receiving riociguat for < 3 months before entry. Median (range) duration of observation and riociguat treatment (days): 475.0 (0.0–1367.0); 455.0 (0.0–1367.0). 
c Preferred-term AEs reported in ≥ 5% of patients in either group. 
d Peripheral edema in 46 patients (8.6%) and edema in 30 patients (5.6%). 
e Peripheral edema in 27 patients (6.4%) and edema in 12 patients (2.9%). 
f RV failure in 34 patients (6.3%) and cardiac failure in 7 patients (1.3%). 
g RV failure in 27 patients (6.4%) and cardiac failure in 9 patients (2.1%). 
h Investigator’s causality assessment. 
i Preferred-term SAEs reported in ≥ 2% of patients in either group. 
j RV failure in 34 patients (6.3%) and cardiac failure in 6 patients (1.1%). 
k RV failure in 25 patients (6.0%) and cardiac failure in 9 patients (2.1%). 
l Preferred term for worsening of the condition.Note. Patients with peripheral edema/edema or RV failure/cardiac failure could have both events. 
H.-A. Ghofrani et al.                                                                                                                                                                                                                           
Respiratory Medicine 178 (2021) 106220
9
patients receiving riociguat either as monotherapy or as part of a com-
bination regimen at baseline was also a strength of the study. 
5. Conclusion 
Final data from the EXPERT registry showed that in patients with 
CTEPH, the long-term safety of riociguat in routine practice, was 
consistent with clinical trials, with no new safety concerns identified. 
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oraria for consultation or speaker fees from Actelion and Merck; and 
research support through his institution from Actelion, Merck, Glax-
oSmithKline, and Ferrer. Joanna Pepke-Zaba reports research grants and 
speaker honoraria/consultancy fees from Actelion, Bayer/MSD, and 
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Gérald Simonneau. Conceptualization; methodology; investigation; 
resources; writing – review & editing; supervision; approval of final draft 
for submission. 
Hossein-Ardeschir Ghofrani. Conceptualization; methodology; 
investigation; resources; writing – review & editing; supervision; 
approval of final draft for submission. 
Henning Gall. Investigation; resources; writing – review & editing; 
supervision; approval of final draft for submission. 
Ekkehard Grünig. Investigation; resources; writing – review & edit-
ing; supervision; approval of final draft for submission. 
Hans Klose. Investigation; resources; writing – review & editing; 
supervision; approval of final draft for submission. 
Michael Halank. Investigation; resources; writing – review & editing; 
supervision; approval of final draft for submission. 
David Langleben. Investigation; resources; writing – review & edit-
ing; supervision; approval of final draft for submission. 
Repke J. Snijder. Investigation; resources; writing – review & editing; 
supervision; approval of final draft for submission. 
Pilar Escribano Subias. Investigation; resources; writing – review & 
editing; supervision; approval of final draft for submission. 
Lisa M. Mielniczuk. Investigation; resources; writing – review & 
editing; supervision; approval of final draft for submission. 
Tobias J. Lange. Investigation; resources; writing – review & editing; 
supervision; approval of final draft for submission. 
Jean-Luc Vachiéry. Investigation; resources; writing – review & 
editing; supervision; approval of final draft for submission. 
Hubert Wirtz. Investigation; resources; writing – review & editing; 
supervision; approval of final draft for submission. 
Douglas S. Helmersen. Investigation; resources; writing – review & 
editing; supervision; approval of final draft for submission. 
Iraklis Tsangaris. Investigation; resources; writing – review & edit-
ing; supervision; approval of final draft for submission. 
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